105 related articles for article (PubMed ID: 1579900)
1. Use of purified dermatan sulfate for heparin cofactor II (HC II) assay.
Ruzzenente O; Ghidini R; Poli G; Schiavon R; Guidi GC
Thromb Res; 1992 Jan; 65(2):281-7. PubMed ID: 1579900
[TBL] [Abstract][Full Text] [Related]
2. Heparin cofactor II assay. Elimination of heparin and antithrombin-III effects.
Nakhleh R; Vogt JM; Edson JR
Am J Clin Pathol; 1988 Mar; 89(3):353-8. PubMed ID: 3348170
[TBL] [Abstract][Full Text] [Related]
3. Dermatan sulfate and heparin can be fractionated by affinity for heparin cofactor II.
Griffith MJ; Marbet GA
Biochem Biophys Res Commun; 1983 Apr; 112(2):663-70. PubMed ID: 6687802
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of thrombin inhibition by heparin cofactor II in the presence of dermatan sulphates, native or oversulphated, and a heparin-like dextran derivative.
Maaroufi RM; Jozefowicz M; Tapon-Bretaudière J; Jozefonvicz J; Fischer AM
Biomaterials; 1997 Feb; 18(4):359-66. PubMed ID: 9068899
[TBL] [Abstract][Full Text] [Related]
5. Role of lysine 173 in heparin binding to heparin cofactor II.
Whinna HC; Blinder MA; Szewczyk M; Tollefsen DM; Church FC
J Biol Chem; 1991 May; 266(13):8129-35. PubMed ID: 1902471
[TBL] [Abstract][Full Text] [Related]
6. Purification and biological property of heparin cofactor II: activation of heparin cofactor II and antithrombin III by dextran sulfate and various glycosaminoglycans.
Yamagishi R; Niwa M; Kondo S; Sakuragawa N; Koide T
Thromb Res; 1984 Dec; 36(6):633-42. PubMed ID: 6084876
[TBL] [Abstract][Full Text] [Related]
7. Different glycoforms of human thrombomodulin. Their glycosaminoglycan-dependent modulatory effects on thrombin inactivation by heparin cofactor II and antithrombin III.
Koyama T; Parkinson JF; Sié P; Bang NU; Müller-Berghaus G; Preissner KT
Eur J Biochem; 1991 Jun; 198(3):563-70. PubMed ID: 1646716
[TBL] [Abstract][Full Text] [Related]
8. A simple method to measure dermatan sulfate at sub-microgram concentrations in plasma.
Dupouy D; Sié P; Dol F; Boneu B
Thromb Haemost; 1988 Oct; 60(2):236-9. PubMed ID: 3217919
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of potentiation of antithrombin III and heparin cofactor II inhibition by sulfated xylans.
Carson L; Doctor VM
Thromb Res; 1990 May; 58(4):367-81. PubMed ID: 1972302
[TBL] [Abstract][Full Text] [Related]
10. Interaction between histidine-rich glycoprotein and platelet factor 4 with dermatan sulfate and low-molecular-weight dermatan sulfate.
Cella G; Boeri G; Saggiorato G; Paolini R; Luzzatto G; Terribile VI
Angiology; 1992 Jan; 43(1):59-62. PubMed ID: 1554154
[TBL] [Abstract][Full Text] [Related]
11. Binding of heparin or dermatan sulfate to thrombin is essential for the sulfated polysaccharide-accelerated inhibition of thrombin by heparin cofactor II.
Yamagishi R; Koide T; Sakuragawa N
FEBS Lett; 1987 Dec; 225(1-2):109-12. PubMed ID: 3691797
[TBL] [Abstract][Full Text] [Related]
12. Fibrinogen inhibits the heparin cofactor II-mediated antithrombin activity of dermatan sulfate.
Zammit A; Dawes J
Blood; 1995 Feb; 85(3):720-6. PubMed ID: 7833476
[TBL] [Abstract][Full Text] [Related]
13. Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II.
Scully MF; Ellis V; Seno N; Kakkar VV
Biochem J; 1988 Sep; 254(2):547-51. PubMed ID: 2902851
[TBL] [Abstract][Full Text] [Related]
14. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.
Okwusidi JI; Anvari N; Kulczycky M; Blajchman MA; Buchanan MR; Ofosu FA
J Lab Clin Med; 1991 May; 117(5):359-64. PubMed ID: 2019790
[TBL] [Abstract][Full Text] [Related]
15. The inhibition of thrombin and chymotrypsin by heparin-cofactor II.
Struss D; Storck J; Zimmermann RE
Thromb Res; 1992 Oct; 68(1):45-56. PubMed ID: 1333106
[TBL] [Abstract][Full Text] [Related]
16. Heparin cofactor II: experimental approach to a new assay and clinical results.
Vinazzer H; Stocker K
Thromb Res; 1991 Feb; 61(3):235-41. PubMed ID: 2028443
[TBL] [Abstract][Full Text] [Related]
17. Effect of sulfated xylans during the interaction of [125I]-thrombin with antithrombin III or heparin cofactor II of human plasma.
Simmons RB; Newton GR; Doctor VM
Eur J Drug Metab Pharmacokinet; 1995; 20(1):73-7. PubMed ID: 7588997
[TBL] [Abstract][Full Text] [Related]
18. Active site for heparin cofactor II in low molecular mass dermatan sulfate. Contribution to the antithrombotic activity of fractions with high affinity for heparin cofactor II.
Mascellani G; Liverani L; Parma B; Bergonzini G; Bianchini P
Thromb Res; 1996 Oct; 84(1):21-32. PubMed ID: 8885144
[TBL] [Abstract][Full Text] [Related]
19. Heparin cofactor II inhibits thrombin-stimulated release of tissue plasminogen activator from cultured human endothelial cells in the presence of dermatan sulfate.
Kaji T; Ejiri N; Hayakawa Y; Hayashi T; Sakuragawa N
Thromb Res; 1990 Jul; 59(2):269-77. PubMed ID: 2122537
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo.
Liu L; Dewar L; Song Y; Kulczycky M; Blajchman MA; Fenton JW; Andrew M; Delorme M; Ginsberg J; Preissner KT
Thromb Haemost; 1995 Mar; 73(3):405-12. PubMed ID: 7545318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
